Stockscreener 앱 받기
2.39
2.14%
0.05
전일 마감가:
$2.34
열려 있는:
$2.33
하루 거래량:
510.62K
Relative Volume:
0.60
시가총액:
$152.20M
수익:
-
순이익/손실:
$-30.92M
주가수익비율:
-3.9642
EPS:
-0.6029
순현금흐름:
$-27.39M
1주 성능:
-2.05%
1개월 성능:
+14.90%
6개월 성능:
+217.10%
1년 성능:
-5.16%
1일 변동 폭
$2.32
$2.48
1주일 범위
$2.15
$2.50
52주 변동 폭
$0.41
$3.90
Tuhura Biosciences Inc Stock (HURA) Company Profile
명칭
Tuhura Biosciences Inc
전화
813-875-6600
주소
10500 UNIVERSITY CENTER DR., TAMPA
Compare HURA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HURA
Tuhura Biosciences Inc
|
2.39 | 152.20M | 0 | -30.92M | -27.39M | -0.6029 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tuhura Biosciences Inc Stock (HURA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-27 | 개시 | Citizens | Mkt Outperform |
| 2025-03-03 | 개시 | H.C. Wainwright | Buy |
| 2024-12-19 | 개시 | Rodman & Renshaw | Buy |
| 2024-11-05 | 개시 | Maxim Group | Buy |
Tuhura Biosciences Inc 주식(HURA)의 최신 뉴스
Form DEF 14A TuHURA Biosciences For: 9 July By Investing.com - Investing.com Nigeria
TuHURA Biosciences, Inc. (NASDAQ: HURA) Files 8-K Report Detailing Company Information and Compliance Updates – Minichart - Minichart
TuHURA Biosciences Expands Use of Revolving Credit Facility - TipRanks
TuHURA Biosciences names Amanda Garofalo as clinical operations SVP - Investing.com
TuHURA Biosciences, Inc.(NasdaqCM: HURA) dropped from Russell 2000 Dynamic Index - marketscreener.com
TuHURA Biosciences, Inc.(NasdaqCM: HURA) dropped from Russell 3000E Index - marketscreener.com
TuHURA Biosciences, Inc.(NasdaqCM:HURA) dropped from Russell Small Cap Completeness Index - marketscreener.com
TuHURA Biosciences, Inc.(NasdaqCM: HURA) dropped from Russell 2500 Index - marketscreener.com
Enterprise value to EBIT forward of TuHURA Biosciences, Inc. – FWB:PL3 - TradingView
TuHURA Biosciences, Inc.(NasdaqCM: HURA) dropped from Russell 3000 Index - marketscreener.com
TuHURA Biosciences, Inc.(NasdaqCM: HURA) dropped from Russell 2000 Index - marketscreener.com
TuHURA Biosciences, Inc.(NasdaqCM:HURA) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
TuHURA Biosciences, Inc.(NasdaqCM:HURA) dropped from Russell 3000 Growth Benchmark - marketscreener.com
TuHURA Biosciences, Inc.(NasdaqCM:HURA) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of TuHURA Biosciences, Inc. – NASDAQ:HURA - TradingView
EBITDA per share of TuHURA Biosciences, Inc. – DUS:PL3 - TradingView
Price to earnings forward of TuHURA Biosciences, Inc. – DUS:PL3 - TradingView
Cash per share of TuHURA Biosciences, Inc. – DUS:PL3 - TradingView
Return on equity % of TuHURA Biosciences, Inc. – DUS:PL3 - TradingView
Enterprise value to revenue forward of TuHURA Biosciences, Inc. – NASDAQ:HURA - TradingView
Net income before discontinued operations of TuHURA Biosciences, Inc. – DUS:PL3 - TradingView
TuHURA Biosciences, Inc. Balance Sheet – DUS:PL3 - TradingView
Form PRE 14A TuHURA Biosciences For: 26 June By Investing.com - Investing.com Nigeria
TuHURA Biosciences (HURA) virtual annual meeting Aug 18; shareholders to vote on 1.88M-share issuance - Stock Titan
TuHURA Biosciences, Inc. Actuals & Estimates (NASDAQ:HURA) - TradingView
TuHURA Biosciences, Inc. Actuals & Estimates (MUN:PL3) - TradingView
HURA Forecast — Price Target — Prediction for 2027 - TradingView
PL3 Forecast — Price Target — Prediction for 2027 - TradingView
TuHURA Biosciences (HURA) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
TuHURA Biosciences (HURA) Dips 4.55% as Shares Approach Key Support LevelLate Stage Breakouts - dars.gov.et
TuHURA Biosciences Inc (HURA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
HURA Stock Price, Quote & Chart - ChartMill
TuHURA Biosciences, Inc. Files Form 8-K with Nasdaq: Corporate Information, Address, and Key Details - Minichart
TuHURA Biosciences Inc (HURA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TuHURA Biosciences Inc (HURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TuHURA Biosciences Inc (HURA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TuHURA Sets 2026 Virtual Annual Meeting, Proposal Deadlines - TipRanks
Shareholder deadlines set for TuHURA (NASDAQ: HURA) 2026 meeting - Stock Titan
TuHURA Biosciences Inc (HURA) Valuation: PE, PB & Fair Value Analysis - TradingKey
TuHURA Biosciences Inc (HURA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TuHURA Biosciences Inc (HURA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TuHURA Biosciences Inc (HURA) Institutional Confidence - TradingKey
TuHURA Biosciences Inc (HURA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Citizens reiterates TuHURA Biosciences stock rating on AML progress By Investing.com - Investing.com Canada
HURA Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineEstimate Revision Count - newsline.com
TuHURA Biosciences (HURA) Rallies 2.8% as Biotech Stock Tests Key Resistance Near $2.50Inside Day Breakout - newsline.com
TuHURA Biosciences (NASDAQ:HURA) files IND for TBS-2025 - grafa.com
TuHURA files IND for TBS-2025 in blood cancer study By Investing.com - Investing.com South Africa
TuHURA files IND for TBS-2025 in blood cancer study - Investing.com
TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers - Moomoo
TuHURA Biosciences Q1 2026 Earnings: EPS Misses Estimates, Stock Rises Despite Wider Loss - newsline.com
Tuhura Biosciences Inc (HURA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):